Monitoring Safety & Efficacy of Rare Gene Therapies During Clinical Development & in the Commercial Setting

Time: 11:15 am
day: Day 2 CLINICAL AM

Details:

• Reviewing the potential direct and indirect risks of genetic therapies
• Implementing safety monitoring before and after approval of bluebird’s gene therapies
• Long-term follow-up of patients receiving genetic therapies now and in the future

Speakers:

Richard Colvin Richard Colvin, MD, PhD, has served as Chief Medical Officer of bluebird since March 2021. Prior to bluebird, Rich was an executive director in translational Read more